Table 1.
Baseline, 12-mo (mean, SD), and change in serum IGF-1, IGFBP-3 and IGF-1/IGFBP-3 molar ratio, stratified by intervention arm.
| Mean (SD) | Change | Change | p | ||
|---|---|---|---|---|---|
| Baseline | 12 month | % | |||
|
CONTROL | |||||
| IGF-1 (ng/mL) | 178.7 (53.4) | 174.0 (53.1) | −4.7 | −2.6 | ref |
| IGFBP-3 (ng/mL) | 5214 (1102) | 5110 (1240) | −104 | −2.0 | ref |
| Molar Ratioł | 0.124 (0.028) | 0.123 (0.027) | −0.001 | −0.4 | ref |
|
EXERCISE | |||||
| IGF-1 (ng/mL) | 172.8 (47.3) | 169.0 (46.2) | −3.8 | −2.2 | 0.81 |
| IGFBP-3 (ng/mL) | 5137 (943) | 4991 (958) | −146 | −2.8 | 0.63 |
| Molar Ratioł | 0.121 (0.025) | 0.122 (0.024) | 0.001 | 0.8 | 0.53 |
|
DIET | |||||
| IGF-1 (ng/mL) | 167.9 (46.0) | 170.3 (45.5) | 2.4 | 1.4 | 0.06 |
| IGFBP-3 (ng/mL) | 5081 (951) | 4921 (1022) | −160 | −3.2 | 0.56 |
| Molar Ratioł | 0.119 (0.024) | 0.125 (0.024) | 0.006 | 5.0 | 0.008 |
|
DIET + EXERCISE | |||||
| IGF-1 (ng/mL) | 177.1 (57.3) | 179.6 (58.5) | 2.6 | 1.4 | 0.06 |
| IGFBP-3 (ng/mL) | 5165 (1051) | 4969 (929) | −197 | −3.8 | 0.31 |
| Molar Ratioł | 0.123 (0.026) | 0.130 (0.028) | 0.007 | 5.4 | 0.004 |
Results from GEE model, comparing change from baseline to 12-months between each intervention group and controls.
ł
Molar ratio = [IGF-1 (ng/mL) × 0.130]/ [IGFBP-3 (ng/mL) × 0.036]